Related references
Note: Only part of the references are listed.Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
Guido Sauter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example
A. R. Hughes et al.
PHARMACOGENOMICS (2009)
Systematic Review of HER2 Breast Cancer Testing
Marta Cuadros et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2009)
Metabolomics: A global biochemical approach to drug response and disease
Rima Kaddurah-Daouk et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Genetic variants contributing to daunorubicin-induced cytotoxicity
R. Stephanie Huang et al.
CANCER RESEARCH (2008)
Gemcitabine and cytosine arabinoside cytotoxicity: Association with lymphoblastoid cell expression
Liang Li et al.
CANCER RESEARCH (2008)
Abacavir hypersensitivity: a model system for pharmacogenetic test adoption
Myla Lai-Goldman et al.
GENETICS IN MEDICINE (2008)
Pharmacogenomics: candidate gene identification, functional validation and mechanisms
Liewei Wang et al.
HUMAN MOLECULAR GENETICS (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis
Sunita J. Shukla et al.
PHARMACOGENETICS AND GENOMICS (2008)
Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation
Fang Li et al.
PHARMACOGENETICS AND GENOMICS (2008)
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans
Nita A. Limdi et al.
PHARMACOGENOMICS (2008)
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics
Hedi Schelleman et al.
PHARMACOGENOMICS (2008)
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population:: comparison with other equations
Alan H. B. Wu et al.
PHARMACOGENOMICS (2008)
Biochemistry - A postgenomic visual icon
John N. Weinstein
SCIENCE (2008)
Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: A 6-month follow-up study
H. Ngow et al.
XENOBIOTICA (2008)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A second generation human haplotype map of over 3.1 million SNPs
Kelly A. Frazer et al.
NATURE (2007)
Population genomics of human gene expression
Barbara E. Stranger et al.
NATURE GENETICS (2007)
Metabolomic mapping of atypical antipsychotic effects in schizophrenia
R. Kaddurah-Daouk et al.
MOLECULAR PSYCHIATRY (2007)
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
J. Kirchheiner et al.
PHARMACOGENOMICS JOURNAL (2007)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity
R. Stephanie Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Mapping genes that contribute to daunorubicin-induced cytotoxicity
Shiwei Duan et al.
CANCER RESEARCH (2007)
Gene-expression variation within and among human populations
John D. Storey et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Relative impact of nucleotide and copy number variation on gene expression phenotypes
Barbara E. Stranger et al.
SCIENCE (2007)
Common genetic variants account for differences in gene expression among ethnic groups
Richard S. Spielman et al.
NATURE GENETICS (2007)
The art and practice of systems biology in medicine: Mapping patterns of relationships
J. van der Greef et al.
JOURNAL OF PROTEOME RESEARCH (2007)
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity
Rong Stephanie Huang et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P. Goetz et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Global variation in copy number in the human genome
Richard Redon et al.
NATURE (2006)
Lipidomics: a global approach to lipid analysis in biological systems
Andrew D. Watson
JOURNAL OF LIPID RESEARCH (2006)
The NCI60 human tumour cell line anticancer drug screen
Robert H. Shoemaker
NATURE REVIEWS CANCER (2006)
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes:: Data from the Italian tamoxifen trial
Bernardo Bonanni et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily - A randomized controlled trial
Paul B. Watkins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Pharmaco-metabonomic phenotyping and personalized drug treatment
TA Clayton et al.
NATURE (2006)
Metabonomic evaluation of idiosyncrasy-like liver injury in rats cotreated with ranitidine and lipopolysaccharide
JF Maddox et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2006)
Thiopurine S-methyltransferase pharmacogenetics:: insights, challenges and future directions
L Wang et al.
ONCOGENE (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The International HapMap Project Web site
GA Thorisson et al.
GENOME RESEARCH (2005)
A haplotype map of the human genome
D Altshuler et al.
NATURE (2005)
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:: proposal for a new dosing regimen
EA Sconce et al.
BLOOD (2005)
Human thiopurine S-methyltransferase pharmacogenetics:: Variant allozyme misfolding and aggresome formation
LW Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
M Wadelius et al.
PHARMACOGENOMICS JOURNAL (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells
MT Liu et al.
ONCOGENE (2004)
Metabonomics and its role in drug development and disease diagnosis
JC Lindon et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2004)
Identification of the gene for vitamin K epoxide reductase
T Li et al.
NATURE (2004)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
S Rost et al.
NATURE (2004)
Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective
LJ Lesko et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Codeine intoxication associated with ultrarapid CYP2D6 metabolism
Y Gasche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
AL Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Integrating ethics and science in the international HapMap project
MW Foster
NATURE REVIEWS GENETICS (2004)
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
M Wadelius et al.
PHARMACOGENOMICS JOURNAL (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Transcriptomic analysis of the NCI-60 cancer cell lines
JN Weinstein et al.
COMPTES RENDUS BIOLOGIES (2003)
Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation
LW Wang et al.
PHARMACOGENETICS (2003)
Pharmacogenetics of oral anticoagulants
AK Daly et al.
PHARMACOGENETICS (2003)
Statin-associated myopathy
PD Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
H Takahashi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Natural variation in human gene expression assessed in lymphoblastoid cells
VG Cheung et al.
NATURE GENETICS (2003)
Overview of the main outcomes in breast-cancer prevention trials
J Cuzick et al.
LANCET (2003)
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia
MA Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
MG Scordo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)
JF Gagné et al.
MOLECULAR PHARMACOLOGY (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians
C Balram et al.
PHARMACOGENETICS (2002)
Interindividual variability in sensitivity to warfarin - Nature or nurture?
R Loebstein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Acute liver failure
RJ Fontana et al.
CURRENT OPINION IN GASTROENTEROLOGY (2001)
Share Paper
